逆转动脉粥样硬化的强效降脂药——瑞旨瑞舒伐他汀.pptVIP

瑞旨用法用量 口服。起始剂量为5mg，一日一次。 对于那些需要更强效地降低LDL-C的患者可以考虑起始剂量10mg，一日一次，该剂量能控制大多数患者的血脂水平。 如有必要，可在治疗4周后调整剂量至高一级的剂量水平。 本品可在一天中任何时候给药，可在进食或空腹时服用。? 谢谢大家 * A number of landmark studies have shown that the reduction of LDL-C with statin therapy improves cardiovascular morbidity and mortality in patients with and without established cardiovascular disease. In both primary and secondary prevention studies a greater reduction in LDL-C resulted in greater reductions in cardiovascular (CV) events. Achieving lower LDL-C levels is 否w increasingly accepted. The data clearly show that whether you have CV or 否t and whatever your baseline LDL-C is, however much you lower LDL-C you reduce CV risk and the lower you can get your LDL-C the better. The international guidelines for screening and intervention are based on evidence such as that presented together with epidemiological data. It is therefore reasonable that the achievement of evidence-based treatment guideline goals can be used as a good surrogate for outcomes data until that becomes available. References Ballantyne C. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 1998;82:3Q-12Q Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with 辛伐他汀 in 20,536 high risk individuals: a randomised 安慰剂-controlled trial. Lancet 2002;360:7–22. Sever, PS et al. Prevention of coronary and stroke events with 阿托伐他汀 in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm: a multicentre randomised controlled trial. Lancet 2003;361:1149-58 Rosensen RS. Exp Opin Emerg Drugs 2004;9(2):269-279. LaRosa J, Grundy S, Waters D, et al. Intensive lipid lowering with 阿托伐他汀 in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435. Adapted from Am J Cardiol 1998;82:3Q-12Q with permission from Excerpta Medica Inc. * * ASTEROID is an open-label, multicentre study eva